Ginkgo Bioworks Holdings Past Earnings Performance
Past criteria checks 0/6
Ginkgo Bioworks Holdings's earnings have been declining at an average annual rate of -13.3%, while the Chemicals industry saw earnings growing at 10.7% annually. Revenues have been growing at an average rate of 13.3% per year.
Key information
-13.3%
Earnings growth rate
-7.7%
EPS growth rate
| Chemicals Industry Growth | 13.1% |
| Revenue growth rate | 13.3% |
| Return on equity | -81.6% |
| Net Margin | -298.8% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ginkgo Bioworks Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 218 | -651 | 250 | 465 |
| 30 Jun 24 | 184 | -898 | 297 | 544 |
| 31 Mar 24 | 209 | -854 | 310 | 554 |
| 31 Dec 23 | 251 | -893 | 351 | 581 |
| 30 Sep 23 | 315 | -857 | 382 | 641 |
| 30 Jun 23 | 326 | -1,224 | 713 | 746 |
| 31 Mar 23 | 390 | -1,719 | 1,080 | 892 |
| 31 Dec 22 | 478 | -2,105 | 1,403 | 1,053 |
| 30 Sep 22 | 528 | -3,530 | 2,088 | 1,860 |
| 30 Jun 22 | 539 | -2,962 | 1,683 | 1,652 |
| 31 Mar 22 | 438 | -2,347 | 1,279 | 1,414 |
| 31 Dec 21 | 314 | -1,830 | 863 | 1,150 |
| 30 Sep 21 | 197 | -276 | 94 | 226 |
| 30 Jun 21 | 133 | -200 | 75 | 209 |
| 31 Mar 21 | 100 | -175 | 50 | 189 |
| 31 Dec 20 | 77 | -127 | 38 | 160 |
| 31 Dec 19 | 54 | -119 | 29 | 96 |
Quality Earnings: DNA * is currently unprofitable.
Growing Profit Margin: DNA * is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DNA * is unprofitable, and losses have increased over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare DNA *'s earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DNA * is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-6.6%).
Return on Equity
High ROE: DNA * has a negative Return on Equity (-81.61%), as it is currently unprofitable.